


PATENT
Atty. Docket No. PP017767.0004

I hereby certify that this paper is being deposited with the United States Postal Service by U.S. Express Mail, Label No. EV 525 254 177 US, in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Nancy A. Swanson

1/13/06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: RHONDA HANSEN
U.S. Application No. 10/501,187
PCT No.: PCT/US03/00657
Intl. Filing Date: January 8, 2003
Priority Date: January 8, 2002
Confirmation No.: 3472
Group Art Unit: Unassigned
Examiner: Unassigned
For: GENE PRODUCTS DIFFERENTIALLY EXPRESSED
IN CANCEROUS BREAST CELLS AND THEIR METHODS
OF USE

TRANSMITTAL FORM

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the "Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)," mailed from the United States Patent and Trademark Office on October 21, 2005, enclosed herewith are the following documents:


1. **COPY:** Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US).
2. Check in the amount of \$130.00 representing the payment for the one-month extension of time fee.
3. **ORIGINAL** signed Declaration form.
4. Power of Attorney to Prosecute Applications Before the USPTO.
5. Statement Under 37 CFR 3.73(b) with copy of the Assignment Document attached thereto. The Assignment was faxed to the Assignment Branch of the PTO for recordation on December 22, 2005.
6. **COPY:** Response re Sequence Listing mailed under separate cover on December 15, 2005 to Mail Stop PCT.
7. Petition for a One-Month Extension of Time Pursuant to 37 CFR 1.136(a)

8. Blanket Petition for Extension of Time and
Authorization Charge/Credit Deposit Account.

9. Return postcard.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By: 
Julia R. Rosenthal
Reg. No. 54,410

Date: January 13, 2006

CHIRON CORPORATION
Intellectual Property Dept.
4560 Horton Street
Emeryville, CA 94608-2916
Telephone: (510) 923-3949
Facsimile: (510) 655-3542




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/501,187	Rhonda Hansen	PP17767.004

27476
Chiron Corporation
Intellectual Property - R440
P.O. Box 8097
Emeryville, CA 94662-8097



INTERNATIONAL APPLICATION NO.	
PCT/US03/00657	
I.A. FILING DATE	PRIORITY DATE
01/08/2003	01/08/2002

CONFIRMATION NO. 3472
371 FORMALITIES LETTER



OC000000017302570

Date Mailed: 10/21/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 07/08/2004
- Copy of the International Search Report filed on 07/08/2004
- Oath or Declaration filed on 07/08/2004
- U.S. Basic National Fees filed on 07/08/2004
- Priority Documents filed on 07/08/2004

DOCKETED on/by 10/24/05 om
Atty. JRR PA
File # PP17767.0004
Due Date 12/21/05 Ext RSS SL5
Final Date 5/21/06 RSD SLB

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821

(e) may be submitted in lieu of a new CRF.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE


Telephone: (703) 308-9140 EXT 225


PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/501,187	PCT/US03/00657	PP17767.004

PATENT
Atty. Docket No. PP017767.0004

I hereby certify that this paper is being deposited with the United States Postal Service by U.S. Express Mail, Label No. EV 525 254 177, in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Nancy L. Swanson

 13, 2001
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: RHONDA HANSEN
U.S. Application No. 10/501,187
PCT No.: PCT/US03/00657
Intl. Filing Date: January 8, 2003
Priority Date: January 8, 2002
Confirmation No.: 3472
Group Art Unit: Unassigned
Examiner: Unassigned
For: GENE PRODUCTS DIFFERENTIALLY EXPRESSED
IN CANCEROUS BREAST CELLS AND THEIR METHODS
OF USE

**BLANKET PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE/CREDIT DEPOSIT ACCOUNT**


Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

If a paper is untimely filed in the subject application by Applicant or his representative and such paper is not accompanied by an effective petition for extension of time, the Commissioner for Patents is hereby petitioned under 37 C.F.R. §1.136(a) for the minimum extension of time required to make said paper timely.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By: 
Julia R. Rosenthal
Reg. No. 54,410

Date: January 13, 2006

CHIRON CORPORATION
Intellectual Property Dept.
4560 Horton Street
Emeryville, CA 94608-2916
Telephone: (510) 923-3949
Facsimile: (510) 655-3542

COPY

13 JAN 2005

COPY

EXPRESS MAIL LABEL NO. EV 687 633 889 US

CERTIFICATION REGARDING SEQUENCE LISTING AND PRELIMINARY AMENDMENT Address to: Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	2300-17767
	First Named Inventor	HANSEN, RHONDA
	Application Number	10/501,187
	I. A. Filing Date	January 8, 2003
	Confirmation Number	3472
	Group Art Unit	
	Examiner Name	
Title: "GENE PRODUCTS DIFFERENTIALLY EXPRESSED IN CANCEROUS BREAST CELLS AND THEIR METHODS OF USE"		

Sir:

Prior to the examination of the above-referenced application on the merits, please enter the amendments below.

AMENDMENTS

In the Specification:

Please insert the attached "Sequence Listing" as separately numbered pages 1 - 128 after the abstract.

REMARKS

Formal Matters

The present application has been amended to insert the Sequence Listing.

No new matter is added.

Certification Regarding Sequence Listing

I hereby certify that the enclosed Sequence Listing is being submitted under 37 CFR §§ 1.821(c) and (e) in paper and computer readable form (Compact Disk labeled 'CRF').

As required by 37 CFR 1.821(f), I hereby state that the content of the paper and computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same. The Computer Readable Format (CRF), being submitted under 37 CFR §§ 1.52(e) and 1.824, is formatted on IBM-PC, the operating system compatibility is MS-Windows and the file listing is:

COPY

COPY

COPY

Seqlist.txt 296 KB created December 15, 2005.

COPY

I hereby certify that the enclosed submission includes no new matter. The Sequence Listing was prepared with the software FASTSEQ, and conforms to the Patent Office guidelines. Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825.

Respectfully submitted,

Dated: December 15, 2005

By: 

James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

COPY

COPY